Christopher Cogle, M.D.

Christopher R Cogle, M.D. - Research & Publications

(352) 733-0972

Request an Appointment

Publications

Minimal Residual Disease By Either Flow Cytometry or Cytogenetics Prior to An Allogeneic Hematopoietic Stem Cell Transplant Is Associated With Poor Outcome in Acute Myeloid Leukemia
Blood Cancer Journal
2017

Peripheral Blood Cytokine Levels After Acute Myocardial Infarction Il-1 Beta- and Il-6-Related Impairment of Bone Marrow Function
Circulation Research
2017

The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail
Oncologist
2017

Circulating Progenitor Cells and Coronary Microvascular Dysfunction: Results From the Nhlbi-Sponsored Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (Wise-Cvd)
Atherosclerosis
2016

Connect Mds/Aml: Design of the Myelodysplastic Syndromes and Acute Myeloid Leukemia Disease Registry, a Prospective Observational Cohort Study
Bmc Cancer
2016

Effect of Melphalan 140 Mg/M(2) Vs 200 Mg/M(2) on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation-a Single Center Experience
Clinical Transplantation
2016

A New Model to Predict Remission Status in Aml Patients Based on Day 14 Bone Marrow Biopsy
Leukemia Research
2016

Clinical Significance of in Vivo Cytarabine-Induced Gene Expression Signature in Aml
Leukemia \& Lymphoma
2016

Cost-Effectiveness of Treatments for High-Risk Myelodysplastic Syndromes After Failure of First-Line Hypomethylating Agent Therapy
Expert Review of Pharmacoeconomics \& Outcomes Research
2016

Ex Vivo Virotherapy With Myxoma Virus Does Not Impair Hematopoietic Stem and Progenitor Cells
Cytotherapy
2016

Angiotensin II Regulation of Proliferation, Differentiation, and Engraftment of Hematopoietic Stem Cells
Hypertension
2016

Endothelial Cell Derived Angiocrine Support of Acute Myeloid Leukemia Targeted By Receptor Tyrosine Kinase Inhibition
Leukemia Research
2015

Pharmacokinetics and Pharmacodynamics With Extended Dosing of Cc-486 in Patients With Hematologic Malignancies
Plos One
2015

Prevention of Ebv Lymphoma Development By Oncolytic Myxoma Virus in a Murine Xenograft Model of Post-Transplant Lymphoproliferative Disease
Biochemical and Biophysical Research Communications
2015

Vitamin D Effect on Umbilical Cord Blood Characteristics: a Comparison Between African Americans and Caucasians
Transfusion
2015

Poor Peripheral Blood Stem Cell Mobilization Correlates With Worse Long-Term Outcomes in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Biology of Blood and Marrow Transplantation
2015

Bone Marrow Characteristics Associated With Changes in Infarct Size After Stemi a Biorepository Evaluation From the Cctrn Time Trial
Circulation Research
2015

A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer
Human Gene Therapy
2014

Response To Letter Regarding Article, 'a Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction: Bm Cd34, Cd11B and Clonogenic Capacity as Biomarkers for Clinical Outcomesandquot;
Circulation Research
2014

Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction Bm Cd34, Cd11B, and Clonogenic Capacity as Biomarkers for Clinical Outcomes
Circulation Research
2014

Functional Integration of Acute Myeloid Leukemia Into the Vascular Niche
Leukemia
2014

Mapping Hematopoiesis in a Fully Regenerative Vertebrate: the Axolotl
Blood
2014

Angiotensin II Regulates Hematopoietic Stem Cell Proliferation, Differentiation and Engraftment Efficacy
Experimental Hematology
2014

Myelodysplastic Syndromes Management and Treatment: a Conceptual Framework
Haematologica
2014

Radiation Alone for Solid Tumors and the Questionable Development of Therapy-Related Myelodysplastic Syndromes
Jnci-Journal of the National Cancer Institute
2014

High Rate of Uncaptured Myelodysplastic Syndrome Cases and An Improved Method of Case Ascertainment
Leukemia Research
2014

The Nhlbi Time Trial: One-Year Results
Circulation
2013

Variable and Decreased Clonogenic Activity of Autologous Bone Marrow in Cell Therapy Patients With Ischemic Heart Disease, and Cd34 as a Biomarker for Clinical Outcomes: Results From the Cardiovascular Cell Therapy Research Network (Cctrn)
Circulation
2013

A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials
Current Atherosclerosis Reports
2013

Parp1 Is Required for Chromosomal Translocations
Blood
2013

Overcoming Chronic Myeloid Leukemia Stem Cell Resistance To Imatinib By Also Targeting Jak2
Jnci-Journal of the National Cancer Institute
2013

The Effect of Timing of Stem Cell Delivery Following Acute Myocardial Infarction: the Nhlbi and Cctrn Time Trial
Circulation
2012

Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery On Left Ventricular Function After Acute Myocardial Infarction the Time Randomized Trial
Jama-Journal of the American Medical Association
2012

A Phase I Study of the Vascular Disrupting Combretastatin, Oxi4503, in Patients With Relapsed and Refractory Acute Myeloid Leukemia (Aml) and Myelodysplastic Syndromes (Mds)
Blood
2012

Safety and Efficacy of Oral Azacitidine (Cc-486) Administered in Extended Treatment Schedules To Patients With Lower-Risk Myelodysplastic Syndromes
Blood
2012

Peripheral Blood Cd34(+) Specific Donor Chimerism Analysis as An Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndromes and Acute Myelogenous Leukemia.
Blood
2012

Extended Dosing of Oral Azacitidine (Cc-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule
Blood
2012

Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: a Single Center Prospective Phase II Study- An Update
Blood
2012

Vascular Disrupting Combretastatins Impair Bone Marrow Endothelial Cells By Depolymerizing the Microtubule Cytoskeleton
Blood
2012

Characteristics of Thawed Autologous Umbilical Cord Blood
Transfusion
2012

Selective Purging of Human Multiple Myeloma Cells From Autologous Stem Cell Transplantation Grafts Using Oncolytic Myxoma Virus
Biology of Blood and Marrow Transplantation
2012

The Small Molecule Inhibitor G6 Significantly Reduces Bone Marrow Fibrosis and the Mutant Burden in a Mouse Model of Jak2-Mediated Myelofibrosis
American Journal of Pathology
2012

Virotherapy Using Myxoma Virus Prevents Lethal Graft-Versus-Host Disease Following Xeno-Transplantation With Primary Human Hematopoietic Stem Cells
Plos One
2012

Acute Myeloid Leukemia Targeting By Myxoma Virus in Vivo Depends On Cell Binding But Not Permissiveness To Infection in Vitro
Leukemia Research
2012

Effect of Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells On Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart Failure the Focus-Cctrn Trial
Jama-Journal of the American Medical Association
2012

Underreporting of Myeloid Malignancies By United States Cancer Registries
Cancer Epidemiology Biomarkers \& Prevention
2012

Single Versus Tandem Autologous Stem Cell Transplantation (Asct) for Multiple Myeloma Patients and Role of Second Salvage Transplant: a Single Center Prospective Phase Ii Study
Biology of Blood and Marrow Transplantation
2012

Developing Mechanistic Insights Into Cardiovascular Cell Therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory Rationale
American Heart Journal
2011

Diagnostic Testing, Treatment, Cost of Care, and Survival Among Registered and Non-Registered Patients With Myelodysplastic Syndromes
Leukemia Research
2011

Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 To 3 Weeks Following Acute Myocardial Infarction On Left Ventricular Function the Latetime Randomized Trial
Jama-Journal of the American Medical Association
2011

Results From Latetime: a Randomized, Placebo Controlled Trial of Intracoronary Stem Cell Delivery Two To Three Weeks Following Acute Myocardial Infarction
Circulation
2011

The Jak2 Inhibitor, G6, Alleviates Jak2-V617F-Mediated Myeloproliferative Neoplasia By Providing Significant Therapeutic Efficacy To the Bone Marrow
Neoplasia
2011

Incidence of the Myelodysplastic Syndromes Using a Novel Claims-Based Algorithm: High Number of Uncaptured Cases By Cancer Registries
Blood
2011

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
Journal of Clinical Oncology
2011

The Stilbenoid Tyrosine Kinase Inhibitor, G6, Suppresses Jak2-V617F-Mediated Human Pathological Cell Growth in Vitro and in Vivo
Journal of Biological Chemistry
2011

High Rate of Uncaptured Myelodysplastic Syndrome Cases At the State Cancer Registry Level
Blood
2010

Acute Myeloid Leukemia Cells Depend On Vegf, Pdgfr and Scf Receptor Signaling: Leukemia Regression With Pazopanib
Blood
2010

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: a Phase I Study
Blood
2010

Leukemia Regression By Vascular Disruption and Antiangiogenic Therapy
Blood
2010

Oncolytic Viral Purging of Leukemic Hematopoietic Stem and Progenitor Cells With Myxoma Virus
Cytokine and Growth Factor Reviews
2010

Multicenter Cell Processing for Cardiovascular Regenerative Medicine Applications: the Cardiovascular Cell Therapy Research Network (Cctrn) Experience
Cytotherapy
2010

Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes.
Clinical Advances in Hematology and Oncology
2010

Myxoma Virus Targets Primary Human Leukemic Stem and Progenitor Cells While Sparing Normal Hematopoietic Stem and Progenitor Cells
Leukemia
2009

Aml Regression By Vascular Disruption With Oxi4503 and Anti-Angiogenesis With Bevacizumab.
Blood
2009

Bone Marrow Stem and Progenitor Cell Contribution To Neovasculogenesis Is Dependent On Model System With Sdf-1 as a Permissive Trigger
Blood
2009

Time From Onset of Acute Anterior Myocardial Infarction Negatively Influences Bone Marrow Cell Function: Preliminary Data From the Nhlbi Cctrn Ancillary Studies
Circulation
2009

Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge
Blood
2009

A Phase 1, Open-Label, Dose-Escalation Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml)
Blood
2009

A Comparative Pharmacokinetic/Pharmacodynamic (Pk/Pd) Evaluation of Azacitidine Following Subcutaneous (Sc) and Oral Administration in Subjects With Myelodysplastic Syndromes (Mds) Or Acute Myelogenous Leukemia (Aml), Results From a Phase 1 Study
Blood
2009

Rationale and Design for Time: a Phase Ii, Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Effect of Timing of Administration of Bone Marrow Mononuclear Cells After Acute Myocardial Infarction
American Heart Journal
2009

Impact of Azacytidine Induction Chemotherapies On Post-Transplant Outcomes in Patients With Myelodysplastic Syndromes
Journal of Clinical Oncology
2009

Aldehyde Dehydrogenase Activity as a Functional Marker for Lung Cancer
Chemico-Biological Interactions
2009

Marrow Cell Therapies for Cardiovascular Diseases
Experimental Hematology
2008

Non-Myeloablative Allogeneic Stem Cell Transplantation To Treat High Risk Heavily Pretreated Multiple
Biology of Blood and Marrow Transplantation
2008

Marrow cell therapies for cardiovascular diseases.
Experimental Hematology
2008

Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry.
Stem Cells
2007

Stem cell research.
Paediatric respiratory reviews
2006

Developmental differences in megakaryocyte maturation are determined by the microenvironment.
Stem Cells
2005

Typhlitis with concurrent appendicitis in a patient with chronic lymphocytic leukemia.
Clinical Advances in Hematology and Oncology
2003

Research Interests

Dr. Cogle's research focus is on human hematopoietic stem cells and cancer initiating cells. Specifically, his laboratory is focused on the following projects:

  • Defining the Hemangioblast Activity of the Human Hematopoietic Stem Cell (HSC)
  • This project aims to define the ability of the human hematopoietic stem cell in repairing injured blood vessels. To test this hypothesis we track blood vessel repair in immunocompromised mice transplanted with human HSC enriched from umbilical cord blood, bone marrow and mobilized peripheral blood. Additionally, we study new blood vessel growth in patients and try to determine to what extent the bone marrow is the origin.
  • Defining the Pathologic Hemangioblast Activity of the Hematopoietic Stem Cell in Cancer Blood Vessel Development
  • This project seeks to define the ability of the hematopoietic stem cell and bone marrow in contributing to the pathologic growth of blood vessels within cancer. To test this hypothesis we analyze blood vessels growing within cancers asking to what extent they are of bone marrow origin. We have developed anti-cancer treatments based on this research.
  • Bone Marrow Cell Injections for Heart Disease
  • This project tests the ability of bone marrow cells to repair hearts after heart attacks. The Cogle laboratory is a core laboratory for the NIH Cardiovascular Cell Therapy Research Network, testing the functional capacity of bone marrow and blood in patients who receive bone marrow injections in their hearts. In addition, new technologies are being developed to enhance the function of bone marrow cells to repair the injured hearts better.
  • Defining the Hemangioblast Activity of Leukemia Stem Cells
  • This project aims to define how leukemias exhibit hemangioblast activity, producing not only malignant leukemic cells but also malignant endothelial cells. The significance of this project is that if leukemia demonstrates hemangioblast activity, the generated malignant endothelia may serve as a sanctuary for later relapse. This begs for an alternative approach to leukemia treatment.

Active Research Studies